


Pso Serious 2024

PsoSerious 2024 is the third report to update on key topics related to access to care and treatment for psoriatic disease (PsD) in Canada since 2014.



BACKGROUND

Reports have been released in **2014, 2018, and 2024** focusing on:

**ACCESS
TO CARE**

**ACCESS TO
PHOTOTHERAPY**

**ACCESS TO
TREATMENT**

In addition to providing updates on these three topics, all three reports also looked at emerging trends:

2014	2018	2024
<ul style="list-style-type: none"> • Changes in the private insurance landscape • Biosimilars (referred to as subsequent entry biologics at the time) 	<ul style="list-style-type: none"> • Expansion of teledermatology • Associated health professionals (nurses, GPs with dermatology specialty) • Expanded section on comorbidities 	<ul style="list-style-type: none"> • Specific advances related to PsD (virtual care, associated professionals) • Equitable access to care and treatment • Diversity and skin of colour • Expanded section on comorbidities • Added rare forms of psoriasis • Added pediatric psoriasis

KEY LEARNINGS



DERMATOLOGIST ACCESS

Despite continued increases in dermatologists, access to them remains a problem especially outside of urban areas and in the territories.

Wait times are not improving, and a 2001 benchmark of 5 weeks for initial dermatology consultation was believed to be “almost impossible to achieve”



PRIMARY CARE CRISIS

Ongoing primary care crisis is making access even more challenging and is increasing wait times, with many people in Canada struggling to find a primary care provider (family doctor, nurse practitioner) in order to obtain a referral to a dermatologist.



PHOTOTHERAPY ACCESS

Phototherapy continues to be recommended as an effective and cost-effective treatment for some people with PsD, however access to clinics remains variable across Canada and the number of clinics continue to decline. Despite some provincial health technology recommendations to publicly fund home narrowband UVB, as of 2024 jurisdictions had yet to act on it.



TREATMENT AFFORDABILITY

Despite many new treatments, and advances, affordable access to treatment remains an issue for many in Canada.



SYSTEMIC BARRIERS

There is a growing understanding of systemic barriers that disproportionately affect the ability for people from Black, Indigenous, and other communities of colour to access care and effective treatment.

There is increasing recognition that skin disease disproportionately affects Indigenous communities—including First Nations, Métis, and Inuit—who often face additional barriers such as cost, limited supply and access to care, long wait times, insufficient community resources, and cultural and socioeconomic challenges.



SKIN OF COLOUR

Increased awareness of the key differences in psoriasis in skin of colour and that more effort is required to increase diversity and inclusion of participants in research and in the medical profession.



COMORBIDITIES

Canadian Dermatologists are starting to better understand the significance of comorbidities and are increasingly screening appropriately however awareness was still not well understood among patients.



PEDIATRIC PSORIASIS

Though there are more treatment options than there were 10 years ago for pediatric psoriasis, we still have a long way to go to be on par with the adult population.



The findings of PsoSerious 2024 will help inform Psoriasis Canada's efforts to improve access to care, treatment, and support.

@psoriasiscan1

